Messenger RNA (mRNA) vaccines have been crucial to containing and controlling the ongoing Covid-19 pandemic. Advances in self-amplifying RNA technology promise to make them even more cost ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims ...

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers UTR Therapeutics Inc. Thu, May 8, 2025 ...

Future Implications for mRNA Therapeutics . The fusion of cell-free gene synthesis and AI-driven optimization is redefining what’s possible in mRNA therapeutic development. ... A 5' UTR language model ...

That left a question mark hanging over mRNA's other UTR. "A lot of attention has been paid to a few individual mutations in the 3'UTR, but not much attention has been paid to the 3'UTR itself.

This research indicates that Doxorubicin (Dox)-resistant TNBC cells exhibit increased glycolysis and ATP generation compared ...

For example, they have characterized the transcriptome (mRNA, lncRNA, and miRNA) of aortas in an atherosclerosis mouse model, both during disease progression and after regression following treatment.

Get Instant Summarized Text (Gist) Variations in mRNA length occur during atherosclerosis progression, with mRNAs showing shorter 5'UTR, 3'UTR, and coding regions.

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants. npj Vaccines , 2025; 10 (1) DOI: 10.1038/s41541-025-01166-1 Cite This Page : ...

Further analysis of the genes transcribed from the genomic island revealed that the 3'UTR of mRNA was processed to generate ManS, a novel small noncoding RNA of 80 nt in length.

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers Provided by GlobeNewswire May 8, 2025 ...